Non-viral CRISPR could overcome cell and gene therapy bottlenecks
A new approach leveraging high-yield CRISPR could make it easier to re-engineer massive quantities of cells for therapeutic applications.
List view / Grid view
A new approach leveraging high-yield CRISPR could make it easier to re-engineer massive quantities of cells for therapeutic applications.
A team of scientists have recently discovered how a new drug called JQ1 which is currently in early-phase human cancer trials, can reactivate latent HIV...